We can't (and shouldn't) expect clinicians without PPE to treat ...

ocular hypertension treatment :: Article Creator

Drugs For Treatment Of Ocular Hypertension

List of drugs/medicine used for Ocular Hypertension

This section is a comprehensive directory of medications for Ocular Hypertension, listing both generic and brand names. It's a useful resource for healthcare professionals and individuals seeking medication information. Click on a medication below to view details including brand names, prices, dosages, side effects, and administration guidelines. Additionally, a FAQs section is available for each medication, addressing inquiries and providing deeper insights into its use for Ocular Hypertension management. We recommend consulting your doctor to verify the information presented on this page or if you need any further clarifications.

Brand Names and Generic Names of Drugs for Treatment of Ocular Hypertension Latanoprostene Bunod Ophthalmic

Latanoprostene bunod ophthalmic belongs to a class of prostaglandin analogs which is prescribed to treat patients suffering from open-angle glaucoma or ocular hypertension.

Netarsudil

Netarsudil, a Rho kinase inhibitor is prescribed for reducing the increased intraocular pressure in adult patients suffering from open-angle glaucoma or ocular hypertension.

Related Drugs by Medical Condition

Glaucoma Medical Treatment: Philosophy, Principles And Practice

Sommer A . Intraocular pressure and glaucoma. Am J Ophthalmol 1989;107:186–8

Article CAS Google Scholar

Anderson DR . Glaucoma: the damage caused by pressure. XLVI Edward Jackson memorial lecture. Am J Ophthalmol 1989;108:485–95

Article CAS Google Scholar

Jay JL, Allan D . The benefit of early trabeculectomy versus conventional medicine in primary open angle glaucoma relative to severity of disease. Eye 1989;3:528–35

Article Google Scholar

Migdal C, Gregory W, Hitchings R . Long term functional outcome of early surgery compared with laser and medicine in open angle glaucoma. Ophthalmology 1994;101:1651–7

Article CAS Google Scholar

Kobelt G . Health economics: an introduction to economic evaluation. London: Office of Health Economics, 1996.

Garratt S, editor. Primary open angle glaucoma: preferred practice plan. San Francisco: American Academy of Ophthalmology, 1989.

Kaufman PL, Mittag TW . Medical therapy of glaucoma. In: Posdos SM, Yanoff M, editors. Textbook of ophthalmology, vol 7, Glaucoma. London: Mosby, 1994.

Coakes RL, Brubaker RS . The mechanism of timolol in lower intraocular pressure. Arch Ophthalmol 1978;96:2045–8

Article CAS Google Scholar

Levobunolol Study Group. Levobunolol: a beta adrenoreceptor antagonist effective in the long term treatment of glaucoma. Ophthalmology 1985;92:1271–6

Searle JB, Lustgarten JS, Podos SM . A clinical trial of metipranolol, a non-cardioselective beta adrenergic antagonist in ocular hypertension. Am J Ophthalmol 1991;112:302–7

Article Google Scholar

Berry DP, Van Buskirk EM, Shields MB . Betaxolol and timolol: a comparison of efficacy and side effects. Arch Ophthalmol 1984;102:43–5

Google Scholar

Van Buskirk EM, Fraunfelder FJ . Ocular beta-blockers and systemic effects. Am J Ophthalmol 1984;98:623.

Article CAS Google Scholar

Wang RF, Searle JB, Rodos SM, Sugrue MF . MK-507 (L-671, 152): a topically active carbonic anhydrase inhibitor reduces aqueous humor production in monkeys. Arch Ophthalmol 1991;109:1297.

Article CAS Google Scholar

Lippa EA, Carben LE, Elinger B, et al . Dose-response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992;100:495.

Article Google Scholar

Strahlman ER, Tipping R, Vogel R . A double-masked randomised 1 year study comparing dorzolamide (Trusopt), timolol and betaxolol. Arch Ophthalmol 1995;113:1009–16

Article CAS Google Scholar

Clineschmidt CM, Williams RD, Snyder E, Adamsons A . The Dorzolamide-Timolol Combination Study Group. A randomised trial in patients inadequately controlled with timolol alone, comparing the dorzolamide-timolol combination to monotherapy with timolol alone. Ophthalmology 1998;105:1952–9

Article CAS Google Scholar

Strahlman ER, Vogel R, Tipping R, Clineschmidt CM . The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996;103:1283–93

Article CAS Google Scholar

Toris CB, Yablonski ME, Camras CB, Brubaker RF . Mechanisms of ocular hypertensive effect of latanoprost and the maintenance of normal blood-aqueous barrier function. Surv Ophthalmol 1997;41 (Suppl 2):569–75.

Google Scholar

Bill A . Uveoscleral drainage of aqueous humor: physiology and pharmacology. Prog Clin BioI Res 1989;312:417–27

CAS Google Scholar

Kaufman PL, Crawford K . Aqueous humor dynamics: how PGF2a lowers intraocular pressure. Prog Clin Biol Res 1989;312:387–416

CAS PubMed Google Scholar

Aim A, Stjernschantz J . Scandinavian Latanoprost Study Group. Effects on lOP and side effects of 0.005% latanoprost OD, evening and morning: a comparison with timolol. Ophthalmology 1995;102:1734–52

Google Scholar

Watson P, Stjernschantz J . Latanoprost Study Group. A six month randomised double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126–37

Article CAS Google Scholar

Camras CB . United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six month masked, multicenter trial in the US. Ophthalmology 1996;103:138–47

Article CAS Google Scholar

Alm A, Wiodengard I, Kjellgren D, et al . Latanoprost administered once daily caused a maintained reduction of lOP in glaucoma patient treated concomitantly with timolol. Br J Ophthalmol 1995;79:12–16

Article CAS Google Scholar

Pulo AH, Greve EL, Hoyng PF . Additive effect of latanoprost, a prostaglandin PGF2 analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899–902

Article Google Scholar

Selen G, Stjernschantz J, Resul B . Prostaglandin-induced pigmentation in primates. Surv Ophthalmol 1997;41 (Suppl 2):S125–8.

Article Google Scholar

Toris CB, Gleason ML, Camras CB, Yablonski ME . Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514–7

Article CAS Google Scholar

Schuman JS . Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41 (Suppl 1):S27–37.

Article Google Scholar

Searle JB . Brimonidine Study Group III. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated IOP. Surv Ophthalmol 1996;41 (Suppl 1):539–47.

Google Scholar

Lachkar Y, Migdal C, Dhanjil S . Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch Ophthalmol 1998;116:1591–4

Article CAS Google Scholar

March WF, Stewart RM, Mandell AI, Bruce LA . Duration of effect of pilocarpine gel. Arch Ophthalmol 1982;100:1270.

Article CAS Google Scholar

Quigley HA, Pollack IP, Harbin TS Jr . Pilocarpine Ocuserts: longterm clinical trials and selected pharmacodynamics. Arch Ophthalmol 1975;93:771.

Article CAS Google Scholar

Clineschmidt CM, Strahlman ER, Anderson K . Timolol/MK507: comparison of a fixed combination of dorzolamide and timolol (b.I.D.) to concomitant administration of dorzolamide (t.I.D.) plus timolol (b.I.D.) in patients with open angle glaucoma for three months. Invest Ophthalmol Vis Sci 1995;36 (Suppl):3405.

Google Scholar

European Glaucoma Society. Terminology and guidelines for glaucoma. Savona: Dogma, 1998.

VVN539 Met Primary Study Endpoints In US Phase IIa Clinical Study For The Treatment Of Glaucoma

SHANGHAI, June 4, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary objective was to evaluate the ocular hypotensive efficacy of 2 concentrations of VVN539 Ophthalmic Solution (0.04% and 0.02%) in patients with POAG or OHT, and the secondary objective was to evaluate the ocular and systemic safety of VVN539 Ophthalmic Solution.

In this double-masked, vehicle and dose-controlled, and parallel first in human study, topical ocular dosing with VVN539 Ophthalmic Solution resulted in a clinically and statistically significant decrease in elevated intraocular pressure (IOP) in subjects with OHT and POAG. The 0.04% VVN539 Ophthalmic Solution was statistically superior to its vehicle at all 9 diurnal time points over the course of the 21 days study. The magnitude of the decrease from unmedicated baseline was 5 to 6 mm Hg. The 0.02% VVN539 Ophthalmic Solution provided statistically significant decreases from unmedicated baseline relative to its vehicle at majority of time points. Consistent with other studies of this type, there was a 1-2 mm Hg reduction in IOP seen in the vehicle group. The results of this Phase 2 study indicate that VVN539 appears safe and well tolerated in adult subjects with POAG or OH.

Overall, VVN539 Ophthalmic Solution exhibited statistically and clinically significant ocular hypotensive activity and was well tolerated for the treatment of patients with primary open-angle glaucoma and ocular hypertension. Further clinical studies of the drug will explore the therapeutic potential in comparison with a first-line hypotensive drug in a lager patient population.

About VVN539

VVN539 is a first-in-class, duo MOA small molecule for the treatment of glaucoma. It acts directly at trabecular meshwork, increases the outflow of aqueous humor, and thus lowers intraocular pressure (IOP). In a preclinical animal model, VVN539 exhibited remarkable IOP lowering efficacy, and this innovative drug is expected to be competitive in the global glaucoma market.

About Vivavision Biotech Ltd.

VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. Besides VVN001 program, VivaVision is developing VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis. Vivavision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases.

VivaVision is led by experienced drug hunters in the fields of ophthalmology. The company is inspired to be a global leader of ophthalmic drug discovery. VivaVision is backed by leading life sciences investors including Sequoia, Lapam, Cenova. CTJA, etc.

To learn more about VivaVision, Visit: www.Vivavisionbio.Com

Media Contact: support@vivavisionbio.Com

View original content:https://www.Prnewswire.Com/news-releases/vvn539-met-primary-study-endpoints-in-us-phase-iia-clinical-study-for-the-treatment-of-glaucoma-301841129.Html

SOURCE VIVAVISION BIOTECH LTD

Search This Blog

Hypertension